 NEW YORK, Feb. 10, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell MPC therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain CLBP due to degenerative disc disease DDD refractory to conventional treatments. The results indicate that a single injection of rexlemestrocel-L may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred. 